Skip to main content

Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy

Effect on outcome and toxicity in locally advanced head and neck cancer

Intensitätsmodulierte Strahlentherapie versus Parotis schonende 3-D- konformale Strahlentherapie

Effektivität und Toxizität der Behandlung beim lokal fortgeschrittenen Kopf-Hals-Karzinoms

Strahlentherapie und Onkologie volume 189, pages 223–229 (2013)Cite this article

Abstract

Background and purpose

Intensity-modulated radiotherapy (IMRT) has rapidly become standard of care in the management of locally advanced head and neck squamous cell carcinoma (HNSCC). In this study, our aim was to retrospectively investigate the effect of the introducing IMRT on outcome and treatment-related toxicity compared to parotid-sparing 3D conformal radiotherapy (3DCRT).

Material and methods

A total of 245 patients with stage III and IV HNSCC treated with primary radiotherapy between January 2003 and December 2010 were included in this analysis: 135 patients were treated with 3DCRT, 110 patients with IMRT. Groups were compared for acute and late toxicity, locoregional control (LRC), and overall survival (OS). Oncologic outcomes were estimated using Kaplan–Meier analysis and compared using a log-rank test. Acute toxicity was analyzed according to the Common Terminology Criteria for Adverse Events v3.0 and late toxicity was scored using the RTOG/EORTC late toxicity scoring system.

Results

Median follow-up was 35 months in the IMRT group and 68 months in the 3DCRT group. No significant differences were found in 3-year LRC and OS rates between the IMRT group and 3DCRT group. Significantly less acute mucositis ≥ grade 3 was observed in the IMRT group (32% vs. 44%, p = 0.03). There was significantly less late xerostomia ≥ grade 2 in the IMRT group than in the 3DCRT group (23% vs. 68%, p < 0.001). After 24 months, there was less dysphagia ≥ grade 2 in the IMRT group although differences failed to reach statistical significance.

Conclusion

The introduction of IMRT in the radiotherapeutic management of locally advanced head and neck cancer significantly improved late toxicity without compromising tumor control compared to a parotid-sparing 3D conformal radiotherapy technique.

Zusammenfassung

Hintergrund und Ziel

Die intensitätsmodulierte Strahlentherapie (IMRT) hat sich in den letzten Jahren als Standard in der Therapie der lokal fortgeschrittenen Plattenepithelkarzinome des Kopf-Hals-Bereichs etablieren können. Das Ziel dieser retrospektiven Studie ist es, die Effektivität und Toxizität der intensitätsmodulierten Radiotherapie (IMRT) mit einer, die Parotis schonenden, 3-D-konformalen Strahlentherapie (3DCRT) bei der Behandlung des lokal fortgeschrittenen Kopf-Hals-Karzinoms zu vergleichen.

Material und Methodik

Insgesamt wurden 245 Patienten mit einem Plattenepithelkarzinom des Kopf-Hals-Bereichs im Stadium III und IV, die zwischen Januar 2003 und Dezember 2010 mit einer primären Strahlentherapie behandelt wurden, in die Studie aufgenommen. Von diesen wurden 135 Patienten mit 3DCRT behandelt, 110 Patienten mit IMRT. Die beiden Gruppen wurden bezüglich akuter und später Nebenwirkungen, lokoregionaler Tumorkontrollrate (LRC) sowie Überlebensrate (OS) miteinander verglichen. Die onkologischen Parameter wurden nach Kaplan-Meier berechnet und mittels Log-Rank-Test verglichen. Die akute Toxizität wurde anhand CTCAE v3.0 evaluiert und die Spättoxizität anhand der RTOG/EORTC-Spättoxizitätskriterien beurteilt.

Ergebnisse

Die mediane Nachbeobachtungszeit betrug 35 Monate in der IMRT-Gruppe und 68 Monate in der 3DCRT-Gruppe. Es fand sich kein signifikanter Unterschied bei der lokoregionalen Tumorkontrollrate und der Überlebensrate nach 3 Jahren zwischen der IMRT-Gruppe und der 3DCRT-Gruppe. Akute Mukositis ≥ Grad 3 wurde in der IMRT-Gruppe signifikant weniger beobachtet (32% vs. 44%; p = 0,03). Späte Xerostomie ≥ Grad 2 trat signifikant seltener in der IMRT-Gruppe im Vergleich zu der 3DCRT-Gruppe auf (23% vs. 68%; p < 0,001). In der IMRT-Gruppe waren nach 24 Monaten weniger späte Dysphagien aufgetreten, gleichwohl war dies nicht statistisch signifikant.

Schlussfolgerung

Die Einführung der IMRT als Standardtherapie bei der Behandlung des lokal fortgeschrittenen Kopf-Hals-Karzinoms hat keinen negativen Einfluss auf den onkologische Erfolg der Behandlung, gleichwohl kommt es zu einer deutlichen Verminderung der akuten und späten Nebenwirkungen verglichen mit der, die Parotis schonenden, 3-D-konformalen Strahlentherapie (3DCRT).

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Bourhis J, Overgaard J, Audry H et al (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843–854

    PubMed  Article  Google Scholar 

  2. Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355:949–955

    PubMed  CAS  Google Scholar 

  3. Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26:3582–3589

    PubMed  Article  CAS  Google Scholar 

  4. Wiehle R, Knippen S, Grosu AL (2011) VMAT and step-and-shoot IMRT in head and neck cancer: a comparative plan analysis. Strahlenther Onkol 187:820–825

    PubMed  Article  Google Scholar 

  5. Veldeman L, Madani I, Hulstaert F et al (2008) Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 9:367–375

    PubMed  Article  Google Scholar 

  6. Eisbruch A, Foote RL, O’Sullivan B et al (2002) Intensity-modulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets. Semin Radiat Oncol 12:238–249

    PubMed  Article  Google Scholar 

  7. Chao KS, Wippold FJ, Ozyigit G et al (2002) Determination and delineation of nodal target volumes for head-and-neck cancer based on patterns of failure in patients receiving definitive and postoperative IMRT. Int J Radiat Oncol Biol Phys 53:1174–1184

    PubMed  Article  Google Scholar 

  8. Gregoire V, Levendag P, Ang KK et al (2003) CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. Radiother Oncol 69:227–236

    PubMed  Article  Google Scholar 

  9. Gregoire V, Eisbruch A, Hamoir M, Levendag P (2006) Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol 79:15–20

    PubMed  Article  Google Scholar 

  10. Maes A, Weltens C, Flamen P et al (2002) Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol 63:203–211

    PubMed  Article  Google Scholar 

  11. Mendenhall WM, Mancuso AA (2009) Radiotherapy for head and neck cancer—is the “next level” down? Int J Radiat Oncol Biol Phys 73:645–646

    PubMed  Article  Google Scholar 

  12. Nutting CM, Morden JP, Harrington KJ et al (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12:127–136

    PubMed  Article  Google Scholar 

  13. Lee NY, de Arruda FF, Puri DR et al (2006) A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66:966–974

    PubMed  Article  Google Scholar 

  14. Chen AM, Li BQ, Farwell DG et al (2011) Improved dosimetric and clinical outcomes with intensity-modulated radiotherapy for head-and-neck cancer of unknown primary origin. Int J Radiat Oncol Biol Phys 79:756–762

    PubMed  Article  Google Scholar 

  15. Clavel S, Nguyen DH, Fortin B et al (2012) Simultaneous integrated boost using intensity-modulated radiotherapy compared with conventional radiotherapy in patients treated with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 82:582–589

    PubMed  Article  Google Scholar 

  16. Vergeer MR, Doornaert PA, Rietveld DH et al (2009) Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 74:1–8

    PubMed  Article  Google Scholar 

  17. Toledano I, Graff P, Serre A et al (2012) Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004-03. Radiother Oncol 103:57–62

    PubMed  Article  Google Scholar 

  18. Nguyen NP, Vock J, Chi A et al (2012) Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer. Strahlenther Onkol 188:677–683

    PubMed  Article  CAS  Google Scholar 

  19. Vissink A, Burlage FR, Spijkervet FK et al (2003) Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med 14:213–225

    PubMed  Article  CAS  Google Scholar 

  20. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM et al (2008) Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 26:3770–3776

    PubMed  Article  Google Scholar 

  21. Dirix P, Abbeel S, Vanstraelen B et al (2009) Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 75:385–392

    PubMed  Article  CAS  Google Scholar 

  22. Levendag PC, Teguh DN, Voet P et al (2007) Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose–effect relationship. Radiother Oncol 85:64–73

    PubMed  Article  Google Scholar 

  23. Eisbruch A, Rhodus N, Rosenthal D et al (2003) How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 13:226–234

    PubMed  Article  Google Scholar 

Download references

Acknowledgment

Maarten Lambrecht is a research assistant (aspirant) of the Research Foundation—Flanders (FWO). A special thanks to Pascal Wolter, MD and Isabelle Kindts, MD for the help in translating the abstract.

Conflict of interest notification

On behalf of all authors, the corresponding author states that there are no conflicts of interest.

Author information

Affiliations

  1. Department of Radiation Oncology, Leuvens Kankerinstituut, University Hospitals Leuven, Campus Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium

    M. Lambrecht M.D., D. Nevens M.D. & S. Nuyts M.D. Ph.D.

Authors
  1. M. Lambrecht M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Nevens M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Nuyts M.D. Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Lambrecht M.D..

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lambrecht, M., Nevens, D. & Nuyts, S. Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy. Strahlenther Onkol 189, 223–229 (2013). https://doi.org/10.1007/s00066-012-0289-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-012-0289-7

Keywords

  • Head and neck neoplasms
  • Intensity-modulated radiotherapy
  • Treatment outcome
  • Toxicity
  • Conformal radiotherapy

Schlüsselwörter

  • Kopf-Hals-Tumore
  • Intensitätsmodulierte Strahlentherapie
  • Behandlungserfolg
  • Toxizität
  • Konformale Strahlentherapie